Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase

Gene Therapy

Volumn 5, Issue 7, 1998, Pages 880-887

  Haberkorn, U ^a   Bellemann, M E ^a   Gerlach, L ^a   Morr, I ^a   Trojan, H ^a   Brix, G ^a   Altmann, A ^a   Doll, J ^a   Van Kaick, G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

FDG; Gene therapy; Hepatoma; HSV thymidine kinase; PET

Indexed keywords

DNA; FLUORINE 18; FLUORODEOXYGLUCOSE; GANCICLOVIR; SODIUM CHLORIDE; THYMIDINE KINASE; TRACER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEVICE; DNA SYNTHESIS; DRUG BLOOD LEVEL; DRUG TRANSPORT; GENE THERAPY; HEPATOMA CELL; HERPES SIMPLEX VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MALE; METABOLIC RATE; MORRIS HEPATOMA; NONHUMAN; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SUICIDE GENE;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0031823233     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300679     Document Type: Article

References (41)

1. Tjuvajev JG et al Imaging the expression of transfected genes in vivo. Cancer Res 1995; 55: 6126-6132.
2. Tjuvajev JG et al. Noninvasive imaging of herpes simplex virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996; 56: 4087-4095.
3. 3H-5-fluorocytosine. J Nucl Med 1996; 37: 87-94.
4. Haberkorn U et al. Monitoring gene therapy with herpes simplex virus thymidine kinase in hepatoma cells: uptake of specific substrates. J Nucl Med 1997; 38: 287-294.
5. Haberkorn U et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12-17.
6. Haberkorn U et al PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumours receiving radiotherapy. J Nucl Med 1991; 32: 1485-1490.
7. Rozenthal JM, Levine RL, Nickles RJ, Dobkin JA. Glucose uptake by gliomas after treatment. Arch Neurol 1989; 46: 1302-1307.
8. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988; 29: 1521-1525.
9. Wahl RL et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography, initial evaluation. J Clin Oncol 1993; 11: 2101-2111.
10. Haberkorn U et al. Multitracer studies during gene therapy of hepatoma cells with herpes simplex virus thymidine kinase and ganciclovir. J Nucl Med 1997; 38: 1048-1054.
11. Sobol RE et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Therapy 1995; 2: 164-167.
12. Izquierdo M et al. Long-term rat survival after malignant brain tumour regression by retroviral gene therapy. Gene Therapy 1995; 2: 66-69.
13. Maron A et al. Gene therapy of rat C6 glioma using adenovirusmediated transfer of the herpes simplex virus thymidine kinase gene: long-term follow up by magnetic resonance imaging. Gene Therapy 1996; 3: 315-322.
14. Keller PM et al. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol 1981; 30: 3071-3077.
15. 11C) thymidine. Proc Natl Acad Sci USA 1972; 69: 988-992.
16. 11C)thymidine for measurement of cell proliferation in fast dividing tissues. Nucl Med Biol 1993; 20: 359-362.
17. Shields AF, Coonrod DV, Quackenbush RC, Crowley JJ. Cellular sources of thymidine nucleotides: studies for PET. J Nucl Med 1987; 28: 1435-1440
18. Shields AF et al. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990; 31: 337-342.
19. Keyes JW. SUV: standardized uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.
20. Haberkorn U et al. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J Nucl Med 1994; 35- 1842-1850.
21. 14C)-glucose during chemotherapy in murine Lewis lung tumour. Nucl Med Biol 1992; 19: 55-63.
22. Haberkorn U et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine- J Nucl Med 1997; 38: 1215-1221.
23. Slosman DO, Pugin J. Lack of correlation between tritiated deoxyglucose, thallium-201 and technetium-99m-MIBI cell incorporation under various cell stresses. Eur J Nucl Med 1994; 35: 120-126.
24. Haberkorn U et al. Metabolic and transcriptional changes in osteosarcoma cells treated with chemotherapeutic drugs. Nucl Med Biol 1994; 21- 835-845.
25. Widnell CC et al. Cellular stress induces a redistribution of the glucose transporter. FASEB J 1990; 4: 1634-1637.
26. Clancy BM, Czech MP. Hexose transport stimulation and membrane redistribution of glucose transporter isoforms in response to cholera toxin, dibutyryl cyclic AMP, and insulin in 3T3 adipocytes. J Biol Chem 1990; 265: 12434-12443.
27. Wertheimer E, Sasson S, Cerasi E, Ben-Neriah Y. The ubiquitous glucose transporter GLUT-1 belongs to the glucose-regulated protein family of stress-inducible proteins. Proc Natl Acad Sci USA 1991; 88: 2525-2529.
28. Steele RJC, Brown M, Eremin O. Characterization of macrophages infiltrating human mammary carcinomas. Br J Cancer 1985; 51: 135-138.
29. Whitford P, Mallon ES, George WD, Campbell AM. Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer 1990; 62: 971-975.
30. 31P NMR spectroscopy. NMR Biomed 1991; 4: 262-267.
31. Pedersen PL. Tumour mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22: 190-274.
32. Arora KK, Pedersen PL. Functional significance of mitochondrial bound hexokinase in tumour cell metabolism. J Biol Chem 1988; 263: 17422-17428.
33. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumour proliferation. Nucl Med Biol 1996; 23: 17-22.
34. 19F-NMR spectroscopy. Int J Rad Appl Instrum A 1986; 37: 695-701.
35. Hoverath H et al. Scatter correction in the transaxial slices of a whole-body positron emission tomograph. Phys Med Biol 1993; 38: 717-728.
36. Ostertag H, Kübler WK, Doll J, Lorenz WJ. Measured attenuation correction methods. Eur J Nucl Med 1989; 15: 722-726.
37. Brix G et al. Use of scanner characteristics in iterative image reconstruction for high-resolution positron emission tomography studies of small animals. Ear J Nucl Med 1997; 24: 779-786.
38. Huang SC et al. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980; 238: E69-E82.
39. Schmidt K, Mies G, Sokoloff L. Model of kinetic behavior of deoxyglucose in heterogeneous tissues in brain: a reinterpretation of the significance of parameters fitted to homogeneous tissue models. J Cereb Blood Flow Metab 1991; 11: 10-24.
40. Lucignani G et al. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure. J Nucl Med 1993; 34: 360-369.
41. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide. Biomedical Simulation Resource, University of Southern California: Los Angeles, 1992.